H.C. Wainwright lowered the firm’s price target on Allogene Therapeutics (ALLO) to $11 from $12 and keeps a Buy rating on the shares after the company priced its previously announced public offering of $175M in common stock. The “unwarranted” share decline provides an attractive entry point for investors, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan
- Allogene Therapeutics Prices Large Common Stock Offering
- Allogene Therapeutics price target raised to $10 from $6 at Jefferies
- Unusually active option classes on open April 15th
- Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00